Nijhawan Pardeep 4

What Happened Pardeep Nijhawan, CEO of Edesa Biotech, was awarded 96,913 restricted share units (RSUs) on May 27, 2026. The grant is reported as an acquisition at $0.00 (i.e., no cash paid) and will convert to common shares as the RSUs vest. This is an equity award (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-27; Form 4 filed 2026-05-29 (timely filing).
• Grant size: 96,913 RSUs; reported acquisition price: $0.00 (no immediate cash cost).
• Vesting: RSUs vest monthly in equal proportions over 36 months beginning on the grant date (see footnote F1).
• Shares owned after transaction: not specified in the provided report.
• Ownership disclaimers: several entities (Pardeep Medicine Professional Corp., The Digestive Health Clinic Inc., 1968160 Ontario Inc.) and a family trust are noted as related to the reporting person; the reporting person disclaims beneficial ownership of those shares except to the extent of his pecuniary interest (footnotes F2, F3).
• Filing accession: 0001171843-26-003797.

Context RSUs are a form of equity compensation that convert into actual shares as they vest; they do not represent immediately tradable shares until vested. This award increases the CEO’s potential future ownership over three years but does not indicate an immediate market purchase or sale. The filing appears timely (reported two days after the grant).